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Edited by Veli-Pekka LehtoAbstract Circulating nucleic acids (CNA) are present in small
amounts in the plasma of healthy individuals. However,
increased levels of plasma CNA have been reported in a number
of clinical disorders like cancer, stroke, trauma, myocardial
infarction, autoimmune disorders, and pregnancy-associated
complications. CNA has received special attention because of
its potential application as a non-invasive, rapid and sensitive
tool for molecular diagnosis and monitoring of acute pathologies
and the prenatal diagnosis of fetal genetic diseases. This review
throws light on the current status of blood CNA as a diagnostic
marker and its potential as a powerful tool in the future.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Plasma DNA1. Introduction
The history of circulating nucleic acids (CNA) dates back to
the 1940s, when Mandel and Me¨tais reported in a French jour-
nal the presence of free nucleic acids in plasma [1]. They were
able to detect free DNA and RNA in blood plasma of healthy
individuals and patients. Unfortunately, their work went
unnoticed probably because of a lack of clear understanding
about CNA at that time. Barring two reports on auto-immune
disorders, systemic lupus erythematosus (SLE) [2] and rheuma-
toid arthritis [3] there were no research articles published
related to CNA for next thirty years. In 1977, Leon et al.
reported high levels of CNA in patients of pancreatic cancer
[4]. Interestingly, they even demonstrated that the plasma
DNA levels in patients actually decreased after chemotherapy.
The importance of CNA was recognized in 1994, when the
presence of mutated oncogenes products (K-ras) was reported
in the plasma of pancreatic cancer patients [5]. In the same
year, the research group of Anker reported N-ras gene muta-
tions in patients with myelodysplastic syndrome (MDS) [6].
In the next 5 years, several other reports followed related toAbbreviations: CNA, circulating nucleic acid; MI, myocardial infrac-
tion; SSc, systemic sclerosis; SCLC, small cell lung carcinoma; SLE,
systemic lupus erythematosus; MSP, methylation speciﬁc PCR; NPC,
nasopharyngeal carcinoma
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DNA in the plasma (or serum) of patients with various human
cancers. Fetal-derived nucleic acids which enter maternal plas-
ma during pregnancy have been shown to have potential uses
in prenatal diagnostic strategies. The last decade has witnessed
a great deal of interest in the subject of CNA with respect to
the pathologies of cancerous and non-cancerous origin like
diabetes, stroke, SLE, trauma, rheumatoid arthritis, inﬂamma-
tion, infection, etc.
The increased levels of circulating nucleic acids (DNA and
RNA) in blood of patients indicated that CNA can be used
as a non-invasive, rapid, sensitive and accurate method of
diagnosis of several diseases. This review presents the existing
knowledge on CNA and its future prospects as a diagnostic/
prognostic marker. Research related to circulating nucleic
acids recovered from other body ﬂuids like urine, milk, cell-
free bronchial lavage, etc. is rare and is not discussed here as
it is beyond the scope of this review.2. CNA in various human diseases
2.1. Cancer
It is known that the products of DNA/RNA in plasma actu-
ally arise from lysis of tumor cells. Activated oncogenes, muta-
tions in tumor-suppressor genes like p53, chromosomal
rearrangements and hyper-methylation of genes are some of
the commonly found genetic variations in cancer. The ﬁrst
two genes whose mutations were studied in plasma of patients
are (i) N-ras in myelodysplastic syndrome (MDS) and myelog-
enous leukemia [6] and (ii) K-ras in pancreatic [5] and colorec-
tal cancer [7]. It has been suggested that p53 can be used as an
early tumor marker to indicate recurrence or distant metasta-
sis. In spite of their predominance, p53 alterations are diﬃcult
to detect because of widespread mutations along several exons
and also due to low sensitivity in detection [8].
In plasma of non-Hodgkin’s lymphoma patients, rearrange-
ments in Ig heavy chain DNA sequences were detected. Simi-
larly microsatellite instability, a feature frequently found in
solid tumors, was ﬁrst detected in plasma of small cell lung car-
cinoma patients [9] and in serum of head and neck carcinoma
patients [10]. The sensitivity of detection of microsatellite alter-
ations is also limited because of the fact that loss of heterozy-
gosity (LOH) is more common than band shifts.
Alteration in global genome hypomethylation and hyperme-
thylation of tumor suppressor genes at CpG islands in the pro-
moter region, are frequently found in several types of tumors.
The methylation pattern of mutated genes like p16, DAPK,blished by Elsevier B.V. All rights reserved.
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is proving to be a speciﬁc tool in lung cancer diagnosis
[11,12]. Changes in hypermethylation pattern of DAP kinase
gene in serum and plasma DNA of small cell lung cancer pa-
tients were noticed in 80% and 40% of these cases, respectively
[13].
Several viruses have also been found to be associated with
diﬀerent cancers. CNA of Epstein Barr Virus (EBV) was ﬁrst
detected by Lo et al. in 1999 in nasopharyngeal carcinoma
(NPC) patients [14]. They correlated the levels of circulating
DNA with clinical stages of the disease. Similarly, human pap-
illoma virus (HPV) was also detected in cervical cancer [15]
and squamous head and neck cancer [16].
RNA has a high tendency to undergo degradation and is
therefore not an attractive molecule as a diagnostic marker
in plasma/serum. Although, tumor speciﬁc transcripts of tyros-
inase mRNA were detected in melanoma patients using
RT-PCR [17], however, two additional tumor markers of
melanoma, gp-100 and MART-1 could not be ampliﬁed, indi-
cating that sensitivity and speciﬁcity need to be evaluated care-
fully and sample size has to be increased, before concluding the
validity of plasma RNA as a marker [18].2.2. Prenatal diagnosis
Placenta is no longer thought to be an impermeable mem-
brane; fetal DNA/RNA circulates freely in maternal plasma.
Since, the rapidly growing fetus and placenta have ‘tumor-like’
characteristics, CNA of fetal origin can be expected to be
found in maternal circulation. Based on this approach, for
the ﬁrst time Lo et al. demonstrated the presence of male fetal
DNA in maternal plasma [19]. To prove that fetal cells in pla-
centa are the source of CNA, they isolated plasma DNA from
pregnant women carrying male fetus and after ampliﬁcation of
the Y-chromosome-speciﬁc gene sequences they correctly iden-
tiﬁed male fetuses in 80% of the cases [19]. Moreover, they also
showed that fetal DNA rapidly cleared after delivery. Later,
Lo suggested ‘hypomethylated mapsin’ as the ﬁrst universal
marker for fetal DNA [20]. Lo has done extensive work on cir-
culating fetal DNA and its aberrations in pre-eclampsia (PE),
chromosomal aneuploidies, RhD-genotyping, etc. Therefore,
fetal DNA can be used for non-invasive diagnosis of paternally
inherited diseases, pregnancy-associated complications and
sex-linked disorders.2.3. Other pathological disorders
The occurrence of CNA gained the interest of a wider scien-
tiﬁc community investigating other pathological diseases like
stroke, autoimmune disorders, myocardial infraction (MI),
diabetes, trauma and even prion diseases. Lo’s group estab-
lished a direct relationship between tissue injury in acute trau-
ma and elevated plasma DNA levels [21]. Similarly, release of
DNA into the peripheral blood can take place in acute stroke
which involves CNS tissue damage. Till date there is no simple
and accurate diagnostic blood test to determine the severity of
stroke. Based on the report of Rainer in 2003 [22], it appears
that a high correlation between plasma DNA concentration
and the severity of stroke can prove to be useful in risk strat-
iﬁcation.
Extending the argument of direct relation between extent of
injury and increase in plasma DNA levels to cardial tissue in
MI patients, Chang et al. showed 10 times higher plasmaDNA concentrations (511 ng/ml) in MI patients than controls
(36.3 ng/ml) [23]. Prolonged ischemia eventually leads to
necrosis and at this time large amount of cell-free DNA is re-
leased into circulation. It appears that plasma DNA can be
used along with the traditional markers of troponin and CK-
MB (MB isoenzyme of creatine kinase) for diagnosis of MI
[23].
Presence of high levels of circulating DNA in patients with
SLE was ﬁrst reported in 1966 [2]. Based on the diﬀerent
DNA banding patterns of lymphocytes and plasma, it was
speculated that DNA found in circulation of SLE and systemic
sclerosis (SSc) patients may be result of an actively produced
‘extrachromosomal DNA’ that may play an important role
in the pathophysiology of autoimmune disorders [24].
Studies by Hoon have suggested that circulating DNA of
diﬀerent forms is very useful in staging, identifying disease pro-
gression and response to therapy in melanoma patients [25].
Tyrosinase mRNA was detected speciﬁcally detected in 67%
of melanoma patients, but not in controls [26]. Detection of
donor-derived DNA in plasma of transplant recipients oﬀers
a new method of monitoring transplant rejection. Bone allo-
transplants undergo rigorous processing and are considered
as non-viable tissue. The donor genetic material may persist
in circulation after bone allotransplantation [27].3. Mechanisms of release of cell-free DNA into circulation
Although the evidences proving the presence of high levels of
circulating DNA and RNA in plasma of patients is increasing
day by day, the actual origin of CNA still remains enigmatic.
In a healthy person, it is believed that CNA enters circulation
via apoptosis of lymphocytes and other nucleated cells. Apop-
tosis as the primary source of CNA has been supported by the
fact that normal plasma DNA on electrophoresis exhibits band
sizes equivalent to a whole number multiple (1  5·) of nucleo-
somal DNA (185–200 bps) [28].
In cancer as well, apoptosis has been advanced as the possi-
ble origin of CNA on the basis of the fact that circulating
DNA often represents ladder like electrophoretic pattern
(e.g. as seen in pancreatic and lung cancer) which is similar
to that shown by apoptotic cells [28,29]. It is important here
to make a note of the fact that apoptosis is a mechanism sup-
posedly lost by proliferating cancer cells and great eﬀorts are
needed to restore programmed cell death in malignant cells.
One of the hypotheses for the origin of CNA in cancer is
based on ‘‘micrometastases’’ of tumor origin which are shed
into circulation. Sorenson [30] and Chen [31] reported that
the amount of DNA isolated from plasma of cancer patients
was actually very high and did not correspond to the number
of cancer cells present in the circulation. In other words, the
number of cancer cells as per the amount of circulating
DNA should have been 10000 cells per ml, while the authors
detected much lower number of cells in plasma. Therefore,
above hypothesis of micrometastases was also rejected.
High amounts of DNA found in plasma of patients with
large or advanced/metastatic tumors [10,4] are thought to arise
from tumor necrosis. However, it was noted that after radia-
tion therapy, which is presumed to induce cell death/necrosis,
circulating DNA levels surprisingly decreased in 90% of
patients. Therefore, the hypothesis based on necrosis mediated
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gested by Leon et al. that the decrease in free DNA levels fol-
lowing radiotherapy may be due to arrest of cellular
proliferation by radiation [4]. Cell-free nucleic acids also can
contain small amounts of DNA of T-cell and mitochondrial
origin.
Enzymes DNase I and II present in circulation degrade
DNA and therefore minimal levels of plasma DNA are de-
tected in healthy people. However, low activity of DNase I
and II are seen in malignant diseases. This is supported by
the fact that inhibitors of DNase have been detected in both
tumors [32] and cells like thrombocytes [33], which explains
why the elevated DNA levels in circulation are noticed. Spon-
taneous and active release of DNA by proliferating cancer cells
is another possibility [34,35] that cannot be ignored as the acti-
vated lymphocytes are shown to release DNA in vitro [35].
As far as fetal DNA is concerned, there are three possible
sources of fetal DNA entering maternal plasma: direct transfer
of DNA, placenta and haematopoietic cells, of which placenta
is believed to be the predominant source.
It is well known that RNA is very labile and easily degraded
by ubiquitously present RNases. So, one would not expect cell-
free RNA in plasma. Surprisingly, the presence of stable
endogenous as well as exogenous circulating RNA in blood
suggests that RNA perhaps contained in apoptotic bodies or
bound to proteins/phospholipids and is therefore protected
from degradation by nucleases [17]. Although, the origin of
RNA entering circulation extends from tumor genes to
house-keeping genes in healthy individuals, the knowledge
on the source of CNA and more importantly the mechanism
remains unanswered. An understanding of these issues will
help in identifying the means of clinical application of CNAs.
A schematic presentation of various possible pathways byFig. 1. Schematic presentation of various pathways by which nucleic acid
haematopoitic cells, etc.which cell-free DNA/RNA is released into circulation is given
in Fig. 1.4. Current methods of CNA analysis
Circulating DNA is commonly isolated using commercial
kits like QIAmp 96 spin Blood DNA extraction kit supplied
by Qiagen. Automated isolated systems like MagNa Pure LC
[36] yield signiﬁcantly higher copy numbers of DNA/RNA
and seem to be better than manual methods. Earlier, plasma
DNA below nanogram levels could not be detected using radio
immunoassay (P32DNA) [4], but now DNA upto picogram
concentrations can be detected using PCR. Presently, real time
quantitative PCR is used for amplifying and quantifying the
circulating DNA/RNA of interest. Light-cycler based real-time
PCR is rapid, eliminates carry-over contamination problems
and does not require post-PCR processing [37]. Plasma
DNA upto 10 ng/ml can be detected using simple ﬂuorescent
dyes, Pico Green reagent [38] and Hoechst 33258 [39]. Total
plasma CNA (DNA + RNA) can be detected using SYBR
Green II dye [40]. In general, plasma DNA concentrations of
healthy individuals ranges from 10 to 50 ng/ml while that of
patients is 100 ng/ml or above.5. Future prospects
Methods of isolation and quantiﬁcation of plasma/serum
DNA/RNA are very crucial in analyzing data. We are in
urgent need of standardization of techniques, careful evalua-
tion and analysis of data according to common parameters like
speciﬁcity and sensitivity. The issue of suitability of plasmas are released into circulation. *Other nucleated cells include T-cells,
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techniques in future can make CNA identiﬁcation and quanti-
ﬁcation a routine biochemical laboratory investigation. Plasma
DNA/RNA testing can also eliminate the conventional
methods of tissue biopsies, CT scan and expensive prenatal
diagnostic tests like chorionic villus sampling (CVS) and
amniocentesis. CNA detection is very challenging but has
enormous utility if adequately managed.
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